Educating nurses in the identification of symptoms and the treatments available will increase the identification and early treatment of GVHD in patients.  Nurses are in a perfect position to include other team members to address the psychosocial and palliative/symptomatic care of patients with GVHD, both acute and chronic.

Education on the use of palliative care resources is important to help hematology oncology clinicians potentially lessen the bias that may surround including “outsiders” in the care of their patients, thus allowing these patients and their caregivers to experience the benefits of this resource earlier in their care.

Cellular therapies are associated with an increased infection risk, and vaccination in these survivors plays a critical role in lowering that risk. Clinicians need to be educated on the importance of vaccination in these survivors as well as the details of dosing and timing of vaccines to best protect this vulnerable population from vaccine-preventable diseases.

The selection of optimal second-line therapy for mantle cell lymphoma (MCL) depends on the age and fitness of the patients as well as the eligibility for transplant or CAR T-cell therapy. In the absence of standard management, patients with relapsed/refractory MCL should be referred for participation in prospective clinical trials investigating novel treatment regimens.